Fibrogen announces presentation of positive interim data from the phase 1b study of fg-3246 (for46) in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mcrpc) at the 2024 american society of clinical oncology annual meeting

San francisco, may 23, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced positive interim results from the dose escalation portion of the investigator-sponsored phase 1b/2 study conducted by the university of california san francisco of fg-3246 (for46), a potential first-in-class anti-cd46 antibody drug conjugate (adc) with a mmae-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mcrpc) at the 2024 american society of clinical oncology (asco) annual meeting.
FGEN Ratings Summary
FGEN Quant Ranking